Nalaganje...
Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
Daclatasvir, a HCV NS5A inhibitor, is a new direct-acting antiviral drug for chronic hepatitis C (CHC). This study aimed to evaluate the efficacy and safety of daclatasvir combined with peginterferon-α (pegIFN-α) and ribavirin (RBV) for the treatment of CHC. The databases of PUBMED, EMBASE, COCHRANE...
Shranjeno v:
| izdano v: | Springerplus |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5023653/ https://ncbi.nlm.nih.gov/pubmed/27652142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-016-3218-x |
| Oznake: |
Označite
Brez oznak, prvi označite!
|